Synaptic plasticity pathway

Synaptic plasticity pathways refer to the complex networks of molecular and cellular mechanisms that regulate changes in synaptic strength and connectivity within the nervous system. These pathways are not a single molecule or receptor but encompass a broad set of processes involving neurotransmitter receptors (such as NMDA and AMPA glutamate receptors), ion channels (including voltage-gated calcium channels), protein kinases (like CaMKII, PKA, PKC), phosphatases (such as calcineurin/PP2B), scaffolding proteins, and transcription factors like CREB[1][2][5][7]. The coordinated activity of these molecules underlies phenomena such as long-term potentiation (LTP) and long-term depression (LTD), which are essential for learning, memory formation, cognitive flexibility, and adaptation to experience[3][6][8]. Dysregulation of synaptic plasticity pathways is implicated in various neurological diseases including Alzheimer's disease, schizophrenia, autism spectrum disorders, intellectual disabilities such as fragile X syndrome[4], and other neuropsychiatric conditions. While many drugs may indirectly affect components within these pathways—such as NMDA receptor antagonists or modulators—there is no single drug that targets "synaptic plasticity pathway" itself because it is not a discrete molecular entity but rather an integrated network of signaling events.

Other names

Synaptic plasticity signalingPlasticity pathwaysNeural plasticity pathways